Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

References

• Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL. Aluminum compounds used as adjuvants in vaccines. Pharm. Res. 7(12), 1282–1288 (1990).
   Google Scholar
• Lawrence GW, Saul A, Giddy AJ, Kemp R, Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 15(2), 176–178 (1997).
   Google Scholar
• Menegon T, Baldo V, Bonello C, Dalla CD, Di Tommaso A, Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur j Epidemiol 15(6), 573–576 (1999).
   Google Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol 6, 495–524 (1995).
   Google Scholar
• •A review of the immunostimulating properties of monophosphoryl lipid A and related compounds.
   Google Scholar
• Brandenburg K, Lindner B, Schromm A et al Physicochemical characteristics of triacyl lipid A partial structure 0M-174 in relation to biological activity. Eur Biochem. 267(11), 3370–3377 (2000).
   Google Scholar
• Pizza M, Giuliani MM, Fontana MR et al Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19(17-19), 2534–2541 (2001).
   PubMed Web of Science ®Google Scholar
• Kensil CR. Saponins as vaccine adjuvants. Grit. Rev. Ther. Drug Carrier Syst. 13(1–2), 1–55 (1996).
   Google Scholar
• •A review of the immunostimulating properties of saponins, including QS21.
   Google Scholar
• Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11(9), 909–913 (1993).
   PubMed Web of Science ®Google Scholar
• Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): the first decade. Immunol. Cell. Biol. 74(1), 8–25 (1996).
   Google Scholar
• Trinchieri G. Interleukin-12 and its role in the generation of Thl cells. ImmunaToday14(7), 335–338 (1993).
   Google Scholar
• McCluskie MJ, Weeratna RD, Davis HL. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 19(17-19), 2657–2660 (2001).
   PubMed Web of Science ®Google Scholar
• Cox JC, Coulter AR. Adjuvants — a classification and review of their modes of action. Vaccine 15 (3), 248–256 (1997).
   PubMed Web of Science ®Google Scholar
• Kenney RT, Regina RN, Pichyangkul S, Price VL, Engers HD. Second meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization, Mondiale de la Sante Fondation Merieux, Annecy, France, 5–7 June 2000. Vaccine 20(17–18), 2155–2163 (2002).
   Google Scholar
• Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 68(3), 258–259 (1974).
   Google Scholar
• Sadoff JC, Ballou WR, Baron LS et al Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 240(4850), 336–338 (1988).
   PubMed Web of Science ®Google Scholar
• Sedegah M, Sim BK, Mason C et al Naturally acquired CDS+ cytotoxic T-lymphocytes against the Plasmodium falciparum circumsporozoite protein. Immunol 149(3), 966–971 (1992).
   Web of Science ®Google Scholar
• Tsuji M, Zavala E T-cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol 19(2), 88–93 (2003).
   PubMed Web of Science ®Google Scholar
• •A thoughtful review and discussion of the potential role of cell-mediated immune responses in protection against the preerythrocytic stage of blaparlim.
   Google Scholar
• Newman MJ, Wu JY, Gardner BH etal. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 15(9), 1001–1007 (1997).
   Google Scholar
• Kumar S, Miller LH, Quakyi IA etal. Cytotoxic T-cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature 334 (6179), 258–260 (1988).
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl. Med. 336(2), 86–91 (1997).
   Web of Science ®Google Scholar
• ••The first demonstration in human volunteers of the efficacy of RTS,S/AS02 vaccination against homologous P falciparum sporozoite challenge in a laboratory setting.
   Google Scholar
• Doherty JE Pinder Tornieporth, M. N et al. A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Ainj Trop. Med. Hyg. 61(6), 865–868 (1999).
   Google Scholar
• Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. I Infect. Dis. 183 (4), 640–647 (2001).
   Google Scholar
• Stoute JA, Kester KE, Krzych U et al Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.j Infect. Dis. 178(4), 1139–1144 (1998).
   Google Scholar
• Bojang IKA, Milligan PJ, Pinder M et al Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falcipamm infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (9297), 1927-1934 (2001).
   Google Scholar
• ••The first demonstration in human volunteers of the efficacy of the RTS,S/AS02 vaccine against natural challenge by P falciparum-infected mosquitoes in a field setting.
   Google Scholar
• Lalvani A, Moris P, Voss G et al. Potent induction of focused Thl-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falcipamm malaria vaccine. I Infect. Dis. 180(5), 1656–1664 (1999).
   Google Scholar
• •A preliminary analysis of the nature of the cell mediated immune responses induced by RTS,S/AS02 in human volunteers.
   Google Scholar